Medical & Industrial Radioisotope Production
Radioisotopes and Radiopharmaceuticals
The radiopharmaceutical market in the United States is estimated at $3 billion annually with most of the production occurring in Canada and Europe using highly enriched uranium. The lack of a domestic supply and the current practice of using for weapons grade material led Congress to pass the American Medical Isotope Production Act in fiscal year 2013. This legislation establishes a program to support
Figure 1. Radiopharmaceuticals produced by compact linacs will bring down the costs of nuclear diagnostics
To meet this growing commercial markets, Niowave has embarked on a major expansion to its current research and development headquarters to include a manufacturing and radioisotope production facility. The new $200 million facility will focus on medical radioisotopes and radiopharmaceutical production with plans to ship the isotopes across the country via air and ground transportation (see Figure 1). The superconducting linacs used to produce radioisotopes will also demonstrate high flux x-ray and neutron sources for our other commercial markets. Groundbreaking for the new facility occurred in 2014, and the facility will be operational in 2015. It is located at the Capitol Region International Airport, near Niowave’s existing headquarters in Lansing, Michigan.
Niowave is pioneering the use of compact, 4 Kelvin (-452°F) superconducting linacs capable of meeting this pressing national need. Our proprietary superconducting electron linac system is easily reconfigured to operate at energy between 20 MeV and 40 MeV, with power levels ranging from 50 to 100 kW to produce a variety of radioisotopes. A compact superconducting accelerator used for radioisotope productions is shown being installed for commissioning at Niowave’s test facility in Figure 2.
Figure 2. A compact superconducting accelerator used for radioisotope production